Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden

Femme et Homme Max 99 ans
AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden MAJ Il y a 4 ans

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPD 1. To assess the effect of aclidinium bromide 400 µg administered twice a day on COPD symptoms including cough in patients with moderate COPD compared to placebo. 2. To assess the effects of aclidin...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations

Femme et Homme Max 99 ans
AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden MAJ Il y a 4 ans

A clinical study to assess the benefits of aclidinium bromide/formoterol fumarate (active treatment) compared with placebo (comparator) in lung volumes, exercise capacity and physical activity after 8-weeks of treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). The study is "randomised" (equal chance of receiving active treatment or comparator) and "double blind" (neither patients nor the study doctor will know the treatment). Ensayo clínico para evaluar los beneficios de bromuro de aclidinio/formoterol fumarato (tratamiento activo) comparado con placebo (comparador) en volúmenes pulmonares, capacidad de ejercicio y actividad física tras 8 semanas de tratamiento en pacientes sintomáticos con enfermedad pulmonar obstructiva crónica (EPOC). El estudio es aleatorizado ( igual probabilidad de recibir tratamiento activo y comparador) y doble ciego ( ni los pacientes ni el doctor del estudio sabrán el tratamiento recibido) To evaluate the effect of aclidinium bromide/formoterol 400/12 micrograms fixed dose combination (FDC) BID on lung hyperinflation compared with placebo in patients with moderate to severe chronic obst...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations